NeoGenomics, Inc.
—- Market cap
- —
- Debt
- +$341.86M
- Cash
- −$159.62M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: NEO stock price vs SYK: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SYK's multiple
Needs SYK P/S.
Implied fair value · at NEO's multiple
Needs NEO P/S.
Metric by metric
Where each company leads, and how wide the gap is.
Price unavailable
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: NEO FY 2025 (ended Dec 31, 2025) · SYK FY 2025 (ended Dec 31, 2025).
Trendline
Nine fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
NeoGenomics, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
STRYKER CORP · implied price per share
Bear
$88.62
Base
$109.63
Bull
$137.00
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.41x
0.71x
Net debt / EBITDA
Leverage against operating earnings
-4.48x
1.88x
Cash and equivalents
Liquid reserves on the balance sheet
$159.62M
$4.01B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LABCORP HOLDINGS INC.
NEO vs LH
QUEST DIAGNOSTICS INC
NEO vs DGX
OPKO HEALTH, INC.
NEO vs OPK
Guardant Health, Inc.
NEO vs GH
Natera, Inc.
NEO vs NTRA
EXACT SCIENCES CORP
NEO vs EXAS
ABBOTT LABORATORIES
NEO vs ABT
JOHNSON & JOHNSON
NEO vs JNJ
BAXTER INTERNATIONAL INC
NEO vs BAX
INTUITIVE SURGICAL INC
NEO vs ISRG
ALIGN TECHNOLOGY INC
NEO vs ALGN
ARTIVION, INC.
NEO vs AORT
$341.86M
$15.86B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.